Who are LOKELMA 5 GM Powder for Oral Suspension's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sps, sodium zirconium cyclic silicate, Patiromer Oral Product, Zirconium Cyclosilicate, Lokelma Oral Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lokelma-5-gm-powder-for-oral-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

LOKELMA 5 GM Powder for Oral Suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LOKELMA 5 GM Powder for Oral Suspension (LOKELMA 5 GM Powder for Oral Suspension) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium binder. Area: Nephrology / Cardiology.

marketed Potassium binder Potassium ion (K+) in gastrointestinal tract Nephrology / Cardiology Small molecule Live · refreshed every 30 min

Target snapshot

LOKELMA 5 GM Powder for Oral Suspension (LOKELMA 5 GM Powder for Oral Suspension) — Steno Diabetes Center Copenhagen. Lokelma (sodium zirconium cyclosilicate) is a potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LOKELMA 5 GM Powder for Oral Suspension TARGET	LOKELMA 5 GM Powder for Oral Suspension	Steno Diabetes Center Copenhagen	marketed	Potassium binder	Potassium ion (K+) in gastrointestinal tract
Sps	SODIUM POLYSTYRENE SULFONATE	Concordia	marketed	Potassium Binder [EPC]		1958-01-01
sodium zirconium cyclic silicate	sodium zirconium cyclic silicate	Peking University First Hospital	marketed	Potassium binder	Potassium ion (K+) in gastrointestinal lumen
Patiromer Oral Product	Patiromer Oral Product	Wake Forest University Health Sciences	marketed	Potassium binder	Potassium ion (K+) in gastrointestinal lumen
Zirconium Cyclosilicate	Zirconium Cyclosilicate	AstraZeneca	marketed	Potassium binder	Potassium ion (K+) in gastrointestinal tract
Lokelma Oral Product	Lokelma Oral Product	St George's, University of London	phase 3	Potassium binder	Potassium ion (K+) in gastrointestinal lumen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium binder class)

AstraZeneca · 1 drug in this class
Peking University First Hospital · 1 drug in this class
St George's, University of London · 1 drug in this class
Steno Diabetes Center Copenhagen · 1 drug in this class
Wake Forest University Health Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LOKELMA 5 GM Powder for Oral Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/lokelma-5-gm-powder-for-oral-suspension. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab